The US Food and Drug Administration has approved a new small molecule drug for patients with small cell lung cancer who are set to receive chemotherapy but may be at risk of damage to their bone marrow. Cosela (trilaciclib) is to be administered before chemotherapy in order to preserve bone marrow and immune system function.
